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Abstract

NOVEL ALLOSTERIC INHIBITORS OF THROMBIN
By Bijoy J. Desai, M.S.
A Thesis submitted in partial fulfillment of the requirements for the degree of Masters of
Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2009

Major Director: Umesh R. Desai
Professor, Department of Medicinal Chemistry
Co-Director: H. Tonie Wright
Professor, Department of Biochemistry & Molecular Biology

Thrombin is a critical enzyme involved in blood coagulation and haemostasis. For
this reason the study of its interactions with substrates, inhibitors and modulator is
essential. It is also a unique enzyme in the serine protease family because unlike enzymes
like trypsin and chymotrypsin its activity is modulated by various endogenous and
exogenous ligands. This is due to the presence of “exosites” on the thrombin surface.
Exosite II, unlike exosite-I, has not been characterized for its allosteric effect. In order to
understand the structural basis of interaction and inhibition of inhibitor 4AS, which
possibly interacts with exosite-II, native bovine thrombin crystals and human thrombin

x

crystals grown in presence of 4-AS were prepared. X-ray diffraction data was collected on
4AS soaks of native bovine thrombin as well as human thrombin crystals. The data were
phased by molecular replacement using appropriate search models. The structures were
refined to R factors of 0.24 and 0.27 for native bovine thrombin-4AS soaks and human
thrombin-4AS co-crystals respectively. Examination of a 2F o -F c electron density map
revealed no density for 4-AS. Low affinity of the inhibitor may be the reason for its
absence in the solved structures. In the process of solving these structures, unliganded
native bovine thrombin in a new crystal form, previously unreported in literature, was
solved. The structure shows an overall topology similar to that found in previously
published thrombin molecules. Examination of the crystal packing shows that the exositeII is solvent exposed. This crystal form can be used in the future to study interaction of
exosite-II ligands.

To characterize the interaction of sucrose octasulfate with thrombin, which may
interact with thrombin exosite-II, fluorimetric equilibrium binding titrations were
performed using the active site fluorescent probe para-amino benzamidine. At
physiological salt concentrations, the K D was found to be ~22 μM, which is lower than
heparin fragment of corresponding length. The higher affinity was attributed to the high
charge density of the ligand. Measurement of K D at different salt concentrations showed a
significant amount of contribution to the binding energy from ionic interactions. Based on
the salt dependence experiments, the number of charged interactions per sucrose
octasulfate molecule interacting with thrombin was found to be 3.5. Competitive
xi

experiments of sucrose octasulfate with FDs (a sulfated dehydro-polymer being
investigated in the lab for its anticoagulant properties) for inhibition of thrombin activity
showed competitive effects that did not appear to follow Dixon-Webb competitive
phenomenon. It was found that sucrose octasulfate itself is a weak inhibitor of thrombin.
To investigate the mode of interaction, co-crystals of sucrose-ocasulfate complexed with
thrombin were prepared. High resolution data (2.2 Å) was collected. The structure solved
using this data showed weak density for two sucrose octasulfate molecules. Sucrose
octasulfate was modeled into this density and refined. The refined structure shows that two
sucrose octasulfate molecules bind to two thrombin monomers of the asymmetric unit at
exosite-II. One of the sucrose octasulfate molecules interacts with both monomers, and
could be present as an artifact of crystal packing. The second molecule interacts with
exosite-II of only one of the thrombin monomers. The key residues involved in the
interaction are Lys236, His91, Arg93 and Arg101.
The thrombin-sucrose octasulfate structure does not show any major deviation from
unliganded structure. It is possible that the conformational change may have been masked
due to crystal packing. Characterization of this novel interaction mode of sucrose
octasulfate interaction with thrombin adds one more candidate to the list of compounds
that interact with exosite-II in a manner very similar to heparin, but unlike heparin can
inhibit thrombin activity.

xii

CHAPTER 1 INTRODUCTION

1.1 Physiological Role of Thrombin
Thrombin (fIIa) is the ultimate trypsin-like serine protease produced as a result of
upstream activation of blood coagulation cascade. Vascular injury triggers this cascade,
which is now understood to be brought about by two convergent pathways: intrinsic
pathway and extrinsic pathway.1,

2

Both pathways converge to generate fXa, which

complexes with factor Va (fVa), tissue factor (TF) and calcium on platelet cell. surface to
form the prothrombinase complex.3-7 This major complex catalyzes the formation of
thrombin from its zymogen, prothrombin (fII).8 fII is biosynthesized in liver in a Vitamin
K dependent manner.9-15
Thrombin serves pivotal function in hemostatis, thrombosis and cell
differentiation (Figure 1).16-19 In a sodium-dependent manner, thrombin catalyzes the
conversion of fibrinogen to fibrin monomers.20 The fibrin monomers so formed rapidly
polymerizes to form a clot, which is stabilized by covalent cross-linking of lysine and
glutamine residues through a reaction catalyzed by transglutaminase action of factor
XIIIa (fXIIIa).

1

Thrombin also activates a metal-dependent carboxypeptidase, thrombin-activable
fibrinolysis inhibitor (TAFI) to TAFIa.21-23 TAFIa removes lysine residues recognized by
fibrinolytic enzymes from cross-linked fibrin clot. In addition to the above stated direct
pro-coagulant actions, thrombin can also activate factors V, VII and VIII, in effect
enhancing its own production.5, 24-28 A group of receptors on platelets called proteinaseactivated receptors (PARs) 1, 3 and 4 have been identified, which are proteolytically
activated by thrombin. This activation has been reported to cause platelet aggregation,
degranulation and surface expression of procoagulant phospholipids.29-32 The activation
of PARs is significantly enhanced by surface glycoproteins GPIbα.33 In contrast to its
pro-coagulant activities, the presence of thrombomodulin (TM), an integral membrane
protein in intact vascular endothelium, converts thrombin into an anti-coagulant, which
can activate protein C (PC). Activated protein C proteolytically deactivates factor VIIIa
(fVIIIa) and fVa. TM is an integral membrane protein in intact vascular endothelium. The
anticoagulant property of thrombin in presence of TM ensures that there is no undue
formation of thrombus.34, 35

2

Figure 1. Role of thrombin in blood coagulation. Procoagulant and anticoagulant actions
of thrombin are shown in red and green lines respectively. Cofactors (if any) for the
reactions are written in blue above the lines. Bold lines and arrows show conversion.red
(\) sign indicates inhibition and (+) indicates potentiation.
3

Thrombin activity is regulated by irreversible serine proteinase inhibitors
(SERPINS) antithrombin-III (ATIII) in blood and heparin cofactor (HCII) in extravascular tissue. Their activity is greatly enhanced by sulfated glycosaminoglycans
(GAGs) heparin sulfate and heparan sulfate.36-38
1.2 Overview of Thrombin Structure
Thrombin (EC 3.4.21.5, MEROPS classification peptidase S01.217 of family
S1A, clan PA(S)39) is a serine protease belonging to the trypsin family. Like trypsin, it
employs the same chemical mechanism for proteolysis. However, in contrast to trypsin,
thrombin is highly selective for its substrate and its activity can be modulated by
cofactors and inhibitors. This property can be attributed to the presence of a series of
insertion loops which bind to cofactors and inhibitors. Thrombin and other serine
proteases like trypsin, chymotrypsin, plasmin and kalikrein have evolved to perform
specialized functions from the same ancestral protein through divergent evolution.40-42
The formation of thrombin from prothrombin occurs by the cleavage of two
peptide bonds viz. R320-I321 and R272-T273 (prothrombin numbering) due to the action
of prothrombinase complex.8 Kinetic studies suggest that there is no particular preference
for the order in which these bonds are broken.43 The products of each of these cleavages
are:

membrane-bound, catalytically-active, meizothrombin and catalytically inactive

prethrombin + prothrombin fragment 1.2 respectively. There is an additional cleavage of
R284-T285 in human prothrombin which does not occur in bovine prothrombin.

4

Figure 2: Activation of Prethrombin. Prethrombin (green) is superposed on
thrombin(blue). Important changes associated with activation involve flipping of Ile-16
and Asp194 to form a salt bridge and movement of Asp189, a residue important for
determining substrate specificity. The model was taken from PDB (PDB ID 1MKX)44
and superposed using superpose utility of CCP4 0.6.2. The figure was generated using
PyMol using PDB coordinates of 1MKX. 1MKX is a co-crystal structure of bovine
thrombin and prethrombin.

The cleavage of R320-I321 is critical for thrombin activation. Crystallographic
analysis of structures of prethrombin and thrombin reveal that the cleavage of the
arginine-isoleucine bond leads to an outside-in flipping of the new amino terminal
isoleucine residue and reorientation of D194 (thrombin numbering45,
5

46

) side chain,

enabling them to form a salt bridge (Figure 2). This leads to a conformational change
making the active site functional and more accessible to the substrate.44, 47
The primary structure of thrombin consists of two polypeptide chains: a short L
chain and a large H chain, covalently linked together by a single disulfide linkage
(Figure 4). H chain resembles the trypsin domain and consists of two β-barrel motifs at
the junction of which are the catalytic residues Ser195, His57 and Asp102 which form
the charge relay system.45 Although the L chain is not involved in any of the major
interaction with substrate or inhibitor, its presence is important for the structural stability
and functioning of the enzyme. This also explains why genetic mutations to important L
chain residues cause severe bleeding disorders.48
Figure 4 and 5. Show the thrombin molecule in standard orientation.45 Thrombin
is a globular protein with a roughly ellipsoid shape. The active site cleft passes
equatorially, bisecting the two β-barrel motifs in a perpendicular fashion. At the centre of
the cleft is the catalytic triad. In contrast to trypsin, the extended nature of the cleft
allows the specificity of the substrate to extend much beyond the P1 specificity position
(see section 1. 1.3).
The entrance to the active site is restricted by two large insertion loops. The first
is a relatively flexible loop called the “149 loop/autolysis loop/γ loop”, named so for its
observed ex-vivo autolysis.49 The second is the rigid “60 loop”. This loop is highly
conserved in thrombin of all vertebrate species and contains a rigid –YPPW- hairpin βturn (see Figure 3).
6

Figure 3. Primary sequence alignment of H chain(top to bottom): human thrombin,
bovine thrombin and bovine chymotrypsin. The alignment was performed using
CLUSTAL-X. The coloring is based on the chemical nature of residue side chains.
Conserved regions are indicated by (*), conserved regions with homologous mutations
are indicated by (:) and semi-conserved regions are indicated by (.).

An examination of electrostatic surface potentials of thrombin reveals the
presence of a polarized surface charge distribution. Three contiguous surface patches, one
of negative potential and two of positive potential, have been identified to be crucial in
cofactor/inhibitor binding and substrate recognition. The first positively charged surface
patch is convex in shape and extends from where the active site cleft levels off (Figure 5,
lower right). This site makes additional interactions with fibrinogen when it binds to
thrombin and hence is termed as “fibrinogen recognition exosite” or “anion-binding
exosite-I”.50 The second, more strongly positively charged surface patch extends from the
7

intermediate portion of the C-terminus helix of the H chain (Figure 5, upper left). Due to
its interaction with heparin this site is termed as “heparin binding site” or “anion-binding
exosite II”.51 A third site which lies near to the S1 specificity pocket consists of a small
positively charged cavity with many ordered water molecules. This site is known to bind
to Na+ ion, which is an allosteric effector of thrombin. Upon binding it converts thrombin
to a kinetically distinct form called “fast” form. The unbound form of thrombin is called
“slow” form. This transitioning from slow to fast form and vice-versa has been shown to
be important for regulation of anticoagulant and procoagulant functions of thrombin.52-57

8

Figure 4. Stereo view of human α-thrombin shown in standard orientation (cartoon
representation). Catalytic triad is shown in stick . The figure was created using
PyMOL0.99.
9

Figure 5. Stereo view of human α-thrombin shown in standard orientation (Electrostatic
surface representation). Catalytic triad is shown in stick representation (Hidden behind
the 60 loop). Important loops are circled.
10

1.3 Active Site Interactions

The center of the active site cleft contains the catalytic triad which divides the
active site cleft into two parts. The interaction of regions in these two halves with the
substrate determines the substrate specificity. The regions are termed “specificity
pockets”. The regions of the active site cleft that interact with the residues of the substrate
before the scissile bond are indicated as S1, S2, S3…Sn, S1 being the region that
interacts with the residue immediately preceding the scissile bond. The corresponding
residues of the substrates are indicated by P1, P2, P3,….,Pn. The regions of the active site
cleft that interact with the residues of the substrate after the scissile bond are indicated as
S1’,S2’,S3’,…,Sn’; S1’ being the region that interacts with the residue immediately after
the scissile bond. The corresponding residues of the substrate are indicated by
P1’,P2’,P3’,…,Pn’ (see Figure 6). (Note that Pn to Pn’ are by definition contiguous in
primary sense in N-terminal to C-terminal direction.)

O

Pn

Sn

S1’
P1’

Sn’
Pn’

N

P1

S1

Sx'
Scissile bond
Px'

Px
H

Sx

Figure 6. Schechter and Berger nomenclature of specificity regions in substrate (P) and
their corresponding specificity pockets in the active site cleft (S) around the scissile
peptide bond (CO-NH).
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Like trypsin, the S1 pocket in thrombin (Figure 7) contains acidic residue Asp189
(thrombin numbering)* at its bottom. Due to this there is a strong preference for basic P1
residue like arginine for binding in this site. However, unlike trypsin, the pocket in
thrombin contains the less bulky residue Ala190. This allows accommodation of more
hydrophobic/uncharged P1 groups. At the entrance to S1 pocket there is an acidic residue
Glu192, which is important in determining specificity of substrate and inhibitor.45, 58-60
On the top of the S1 binding pocket extends a hydrophobic region, the base of which is
formed by Trp215 indole moiety. This region is subdivided into S2 cavity and the aryl
binding S4 groove.
The S1’ pocket is limited in size by Lys60f residue of the 60 loop and can only
accept P1’ residues with small polar side chains. The S2’ region is made up of less bulky;
hydrophobic residues and hence can accept P2’ residues with bulky and hydrophobic side
chains. S3’ region is wide, slightly acidic and prefers basic P3’ residues.
1.3.1 PPACK-thrombin Interaction
PPACK

(D-Phenylalanyl-L-prolyl-L-arginyl-chloromethyl

ketone)

is

an

irreversible covalent inhibitor of thrombin.61 Its crystal structure illustrates the role of
specificity pockets in binding peptidyl substrates (Figure 8). The three residue peptidyl
moiety of PPACK fits snugly in the active site pocket; making three hydrogen bonds with
the extended thrombin segment Ser214 to Glu217 in a twisted anti-parallel manner.
*Footnote: The thrombin numbering system is based on topological equivalence
of residues to chymotrypsin residues.
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The C-terminal P1-R carbonyl group covalently links to Ser195 Oγ and His57
Nε2 via the tetrahedral hemiketal and methylene group. The side chain of the P1-R group
fits into the S1 specificity pocket, forming a charged hydrogen bond with Asp189,
Gly219 and a buried water molecule. The P2-Pro of PPACK fits into S2 cavity. The
benzyl side chain of D-Phe moiety extends into the wide S4 aryl-binding site. With
natural substrates, this site is occupied by P4 L-amino acyl side chain. The P3 side chain
for substrates usually points away from the active site cleft. By comparing various
substrates sequences that interact with the active site cleft, an optimal consensus
sequence of FXPRSFR corresponding to P4 P3 P2 P1 P1’ P2’ P3’, has been deduced
(Table 1).62-67 This sequence has been extremely useful for designing active site directed
reversible inhibitors. As seen in Table 1 some substrates do not make optimal
interactions with the active site. These substrates usually utilize additional binding sites
distant from the active site cleft viz. Na+ binding site, anion-binding exosite-I or anion
binding exosite-II.

13

Figure 7. Interaction of PPACK with human α-thrombin. P1-Arg-CH 2 , P2-Pro, P4-Phe
and the catalytic triad (hidden behind the 60 loop) are shown in stick representation.
14

Table 1. Substrate sequences interacting with the active site of thrombin. The scissile
bond is indicated by ( ). This figure was modified from Reference 17.
P3 P4 P2 P1 P1’P2’P3’

Substrate
Fibrinogen Aα
Fibrinogen Bβ
Factor V
Factor V
Factor V
Factor VIII
Factor VIII
Factor XI
Factor XIII
PAR 1
Protein C
TAFI
AT III
HC II
Consensus sequence

15

1.4 Interactions of Anion-binding Exosite I
Exosite I is a surface depression which starts at the end of the P’ side of the active
site cleft approximately 20 Å away from the catalytic triad. It is mainly formed by
insertion loops 70 to 80 (equivalent to the calcium binding loop of trypsin but the Ca2+
ion replaced by Lys70 amine group68) with some bordering residues from 37 loop and
Lys-109, Lys-110 side chains. The base of this depression is formed by the exposed
hydrophobic side chains of Tyr-76 and Ile-82 which is surrounded by cationic side chains
of lysines : 149E, 36, 109, 110, 81 and 70, and arginines 77A, 75, 67, and 73 (see Figure
8).45,

68, 69

Exosite I is known to interact with fibrinogen, PARs, fV, fVIII, fXI, HCII,

hirudin, TM and staphylocoagulase. 32, 70, 71
1.4.1 Thrombin-Hirudin Interaction: A Prototypic Exosite I interaction
Hirudin is a 65 amino acid protein which was discovered in salivary secretions of
European leech Hirudo medicinalis.72,

73

It is one of the most potent and selective

thrombin inhibitor with a K D in femto-molar range. Since it was one of the first thrombin
inhibitor investigated for binding to both exosite-I and the active site, it became a model
for interaction of thrombin with thrombomodulin, PARs and fibrinogen.

16

Figure 8. Electrostatic potential surface of thrombin centered on anion-binding exosite-I.
mportant residues comprising the exosite are labeled and shown in stick representation.
17

The crystal structure of thrombin-hirudin complex shows that the C-terminal
domain of the inhibitor interacts extensively with exosite I by both hydrophobic and
electrostatic interactions, accounting for high specificity of the inhibitor.74,

75

The N-

terminal domain binds to the active site, making several non-polar contacts in the active
site cleft.76,

77

Mutagenesis studies by Stone et. al. show that substitution of acidic

residues on the C-terminal domain reduces the association rate of complex formation and
decrease the affinity. A similar lowering of affinity is observed when hydrophobic
residues are substituted.78
Comparison of the NMR structure of free hirudin with the thrombin bound form
shows that in free form the N-terminal end of hirudin is disordered, and upon binding to
thrombin adopts a 3 10 -helical form.74,

79, 80

This gives rise to a large change in heat

capacity. An unusually large change in heat capacity and an entropy deficit associated
with the formation of an ordered structure when hirudin binds to thrombin suggests an
induced-fit mechanism of binding. This mechanism has been supported by kinetic
studies.81,

82

A binding model based on initial recognition by electrostatic steering by

complementary charged interactions followed by change in inhibitor structure to make
optimum hydrophobic interaction has been proposed.
1.5 Interactions of Anion-binding Exosite-II
The mapping of heparin binding exosite-II was done using a combination of sitedirected mutagenesis and functional studies of heparin induced AT-III inhibition of
thrombin. Exosite-II covers an area of approximately 200 Å2. (upper left corner of
18

Figure5) It is located near the C-terminus of the H-chain of thrombin, centered on the
groove formed by Leu234 and surrounded by basic side-chains of Arg93, Arg101,
Arg165, Arg233, Arg126, Lys236, Lys235, Lys240 and His91. (see Figure 9) The
charges of most of these basic residues are not compensated by acid residues and
therefore exosite-II has the highest charge density on the thrombin surface. The kringle-2
domain of prothrombin forms a non-covalent adduct with exosite-II, indicating that it is
not solvent exposed in the zymogen.
Besides heparin, many ligands interacting with exosite-II have been identified.
Platelet receptor GpIbα, which acts as a cofactor for activation of PARs, interacts with
thrombin utilizing exosite-II. Prothrombin fragment 1.2, CS moiety of TM and fVIII
interact with thrombin via exosite-II. Many exogenous natural inhibitors like Haemadin
form Haemadipsa sylvestris leech, interacts with thrombin via exosite II and the active
site. Due to their polyanionic nature, many DNA and RNA aptamers have been designed
to interact with exosite-II.83,
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Recently, Suramin was shown to inhibit thrombin by

binding to exosite-II.85
1.5.1 Thrombin-heparin interaction
Naturally occurring heparin is a sulfated GAG composed of repeating iduronic
acid and N-acetyl glucosamine units with variable sulfation pattern and chain length. As a
result heparin is inherently polydisperse. It is primarily composed of a major (~75-95%)
trisulfated disaccharide repeating unit consisting of 2-O-sulfo-α-L-iduronic acid 1→4
linked to 6-O-sulfo-N-sulfo-α-D-glucosamine (→4]IdoA2S(1→4)GlcNS6S[1→) along
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Figure 9. Stereoview of anion binding exosite-II represented by semi-transparent
electrostatic surface. Red and blue indicate electropositive and electronegative regions
respectively. Important residues are labeled and represented in stick overlaid with semitransparent electrostatic surface.
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Figure 10. The structures of the major (A) and minor (B) repeating sequences of heparin.
X = SO 3 - or H and Y = SO 3 - or COCH3.
with a number of additional minor disaccharide structures corresponding to its variable
sequence (Figure 10). There is a unique sequence combination that makes specific
interaction with AT-III, called the pentasaccharide sequence. It is composed of
GlcNAc/NS6S → GlcA → GlcNDS3S,6S → IdoA2S → GlcNS6S.
Heparin enhances AT-III mediated inhibition of thrombin by two mechanisms.
Binding of pentasaccharide sequence to AT-III induces an allosteric change in the
conformation of AT-III, making it more reactive towards thrombin. If the heparin chain is
sufficiently long, sequence distal to the pentasaccharide binding site interacts with
exosite-II of thrombin, effectively bridging the two molecules and thereby increasing
their effective concentrations. (see Figure 11) In combination, these two mechanisms
enhance thrombin-ATIII reaction more than 1000 fold. The ternary complex of
antithrombin-thrombin-heparin complex has been independently solved by two
groups.86,87
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Figure 11. Mechanism of heparin induced inhibition of thrombin by AT-III. (A)
Pentasachharide sequence (ball and stick) of heparin binds to AT-III (cartoon
representation) and induces allosteric unfolding of reactive centre loop (circled) making it
more flexible. (B) Ternary complex of thrombin (cartoon representation colored pink)antithrombin(cartoon representation in multiple coloring)-heparin (ball and stick
representation with 2Fo-Fc electron density contoured at 1σ shown in blue). PDB code:
1TB6. This figure is taken form Reference 87.
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Thermodynamic studies of thrombin-heparin interaction show that binding of
heparin to thrombin is non-specific and depends on heparin chain length. High salt
dependence of K D indicates that a major component contributing to the binding energy is
ionic. The crystal structure of PPACK-thrombin bound to heparin (1XMN) is consistent
with this hypothesis. The structure consists of two heparin octasaccharides, each
sandwiched between two thrombin molecules. Both heparin sequences interact differently
with each of the thrombin molecules (through exosite-II), but in both the cases, the
heparin chain makes extensive contacts with one and fewer contacts with the other
thrombin molecules, indicating that the latter interactions are just to compensate the
residual charge. Exosite residues that interact with heparin are R93, H91, R101, R126,
R165, H230, R233, W237 and K240.51 (see Figure 12 and 13)
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Figure 12. Crystal structure of thrombin bound to heparin (PDB ID:1XMN). The
thrombin monomer (monomer AB) making extensive contacts with heparin is shown by
semitransparent electrostatic surface potential (red is negative and blue is positive).
Heparin is shown in ball and stick representation.
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Figure 13. Schematic representation of the two heparin chains interacting with two
thrombin monomers (A) AB and GH and (B) CD and EF respectively in the crystal
structure of thrombin bound to heparin (PDB ID:1XMN). Ionic interactions are indicated
by solid lines, dashed lines indicate hydrogen bonds, solvent mediated hydrogen bonds
are shown by dotted-dashed line and jagged dotted line indicates potential ionic
interaction for incompletely built side-chains. This figure was taken from Reference 51.
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1.5.2 Sucrose Octasulfate: A Heparin Mimic?

Figure 14. Structure of sucrose octasulfate.
Sucrose octasulfate (see Figure 14) has long been considered to be a heparin
mimic, in that it can dimerize Fibroblast growth factors (FGFs) in a manner similar to
heparin.88-91 It has also been reported to bind and activate HC-II to a small degree.92
However it has not been rigorously demonstrated to mimic heparins anticoagulant
properties.
1.6 Interactions at the Na+ Binding Site
The discovery that thrombin is a monovalent cation-activated enzyme was first
reported by Orthner et. al. in a seminal paper of 1980.93 The study showed that Na+ and
other monovalent cations like K+ and Rb+, but not NH4+ or Li+ increased the efficiency of
cleavage (k cat /K m ) of several chromogenic substrates by ~ 10 fold. The study also
showed a Na+ dependent decrease in the clotting time. The binding constant for thrombin
was found to be 20mM at 30 ⁰C. The binding o f Na+ lead to a change in UV absorbance
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difference spectra in the absorption range of Tyr residues. This was inferred to be due to
a change in conformation of thrombin on Na+ binding. The subsequent three decades of
research on this topic has led to a tremendous amount of information to explain the role
of Na+ as an allosteric effector of thrombin. Most of the information is derived by
exploiting three techniques: kinetics, mutagenesis and crystallography, and quite often,
the inferences drawn from these studies are conflicting.
The exact location of Na+ binding remained elusive until much after the
discovery of the role of Na+ as an allosteric effector inspite of several reported thrombin
structures. This was due to the similarity in the observed electron density of Na+ ion and
water. In 1992 Tulinsky et. al. crystallographically identified the Na+ binding site by
exchanging Na+ with Rb+.55 Subsequently, Na+ was identified in several previously
reported crystal structure where it was wrongly assigned to be an ordered water molecule.
Na+ binding site is located in a narrow solvent filled cavity near Asp189 of the S1
pocket. The cavity is 8 Å

18 Å in volume and is formed by four antiparallelβ -strands

between Cys182-Cys191 and Val213-Tyr228. The cavity extends from the active site to
the opposite surface of thrombin. The Na+ ion is octahedrally coordinated with peptide
carbonyl oxygen atoms of Arg221A and Lys224 and four conserved water molecules.
This is further stabilized by interaction of the waters with side-chains of Asp189, Asp221
and main chain atoms of Gly223 and Tyr184A. (see Figure 15)
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Figure 15. Molecular environment of Na+ (yellow sphere) binding site in relation to S1
specificity pocket. Thrombin is shown in cartoon representation (light blue). Important
residues interacting with Na+ are shown in stick representation. Water molecules are
shown as red spheres. P1 Arg side-chain of PPACK is shown in stick representation
(yellow).
The effect of Na+ on the physiological substrates of thrombin shows an increase
in rate of release of fibrinopeptide A and B, and cleavage of PARs. On the other hand,
binding of Na+ decreases the specificity of thrombin for protein C activation. Since it was
seen that binding of Na+ to thrombin generally increased the rate of hydrolysis of
substrates the Na+ bound form was termed as “fast” form and the Na+ free form was
termed as “slow” form. The relevance of the two thrombin forms to blood coagulation is
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still a contentious issue as Na+ levels in blood are tightly regulated. Although, it has been
reported that elevated and decreased levels of Na+ can lead to thrombosis and bleeding
respectively. The temperature dependence of K D of Na+ shows that at physiological
temperature and Na+ concentrations (143 mM) both slow and fast forms are equally
populated.20
Apart from the change in UV absorbance difference spectrum reported by Orthner
et. al., evidence of a global conformational change comes from circular dichroism
studies, which show a loss of ellipticity in the far UV region, implying a change in
packing of certain aromatic residues. Near UV CD spectra show evidence for change in
local asymmetry of aromatic residues. The CD spectra of thrombin in absence and
presence of Na+ grossly overestimate the amount of secondary structure in thrombin,
indicating the contribution of packing of aromatic side chains and disulphide bonds to the
CD signal. It is likely instead, that binding of Na+ to thrombin causes a conformational
change of aromatic residue side-chains (and disulphide linkages) in loop regions of
thrombin. Evidence that Trp residues are involved comes from the reported ~20%
increase in intrinsic fluorescence of thrombin upon Na+ binding.94, 95
Careful kinetic studies indicate that Na+ binding increases the rate of association
of substrate binding (k 1 ) and also the rate of deacylation (k cat ), which is the final step in
the catalytic cycle. Form this study and from previous observations of a general trend for
increase in K m upon Na+ binding, it was concluded that the conformational change
induced upon Na+ binding must be large enough to cause a general widening of the active
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site cleft which remains in that configuration throughout the catalytic cycle of the
enzyme. This effect is even more accentuated for substrates or inhibitors having
significant interaction with the aryl binding pocket. This is exemplified by Y3A mutant
of N-terminal peptide of hirudin. The Tyr3 residue occupies the aryl binding pocket of
the active site and the wild type peptide binds with 35 fold higher preference for the Na+
bound form of thrombin. This preference is reduced to 1.3 fold in the Y3A mutant. This
suggests that Na+ binding especially leads to widening of the aryl binding pocket.96
Apart from its allosteric effect on the active site, Na+ binding is linked to changes
in the exosite-I as well. It has been observed that binding of C-terminus peptide of
hirudin to the exosite-I exhibit the same changes to the kinetics of chromogenic substrate
cleavage as does Na+ binding. Thrombin bound with hirudin at exosite-I shows no further
change in kinetic properties upon Na+ binding. On the other hand, activity of Na+ bound
thrombin does not change upon hirudin binding. Furthermore, affinity of hirudin for the
fast form of thrombin is higher than that for the slow form. All this evidence suggests an
allosteric linkage between Na+ binding site and exosite-I. Various residues energetically
linked to Na+ binding have been mapped by extensive mutagenesis studies. The domains
linked to Na+ binding are clustered in the Na+ binding site, active site and exosite-I. This
means that the conformational change linked to Na+ binding must occur at specific
regions and do not affect the secondary structure and global tertiary structure, as
supported by the interpretation of UV and CD spectra. Finally, the residues at sites other
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than the above stated ones might be involved in the allosteric communication between the
active site, Na+ binding site and exosite I.95, 97
The structural evidence of thrombin slow
→fast allostery is complicated by
several issues. Firstly, most of the previously published thrombin crystals were grown in
solutions containing Na+ as a part of the crystallization buffer. Secondly, irrespective of
the presence or absence of Na+ at the Na+ binding site, the reported structures were
always in the fast form as most of the structures were crystallized with an active site or
exosite-I ligand. This is because of the well known communication among the three sites
and the fact that binding of these ligands mimic the conformation of the fast form.
Finally, crystal contacts themselves make a free energy contribution of ~3-6 kcal/mol,
which is significantly higher than the energy difference between the two forms, implying
that crystal contacts can mask any conformational changes due to slow→ fast allostery.
Recently, several crystal structures of the slow form of wild-type or mutant thrombins
have been published. By comparing the main chain RMSDs (Cα RMSD) of these
structures with the PPACK thrombin structure published by Bode et. al. (PDB ID: 1PPB)
two classes of structures emerge: a) Class I structures with Cα RMSDs comparable to the
RMSDs of other published fast forms of thrombin ( ~0.4 ) and b) Class II structures with
3 fold higher Cα RMSDs compared to other published fast forms of thrombin (~1.25).
(See Table 2) If we consider the average Cα RMSDs of all the fast forms (~0.4) as noise
then the ratio of average Cα RMSDs of each residue of all the class I and
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Table 2. Fast and slow structures submitted in the PDB and their respective Cα RMSD as
compared to 1PPB
Structure PDB ID
Details
Cα RMSD vs. 1PPB
Fast forms
1PPB
1.9 Å, PPACK inhibited
1HAH
2.3 Å, Na+ and hirugen
0.35
bound
1HXF
2.1 Å, Hirugen bound, Na+
0.37
free
1SG8_B
2.3 Å, Na+ bound, R77aA
0.40
2.3 Å, Na+ bound, R77aA
1SG8_E
0.45

Putative slow forms
Class I
1SGI_B
1SGI_E
Class II
2AFQ_B
2GP9
1RD3_B
1RD3_D

2.3 Å, Na+ free from of
1SG8
2.3 Å, Na+ free form of
1SG8
1.9 Å , Na+ free, wild type
1.9 Å, Salt-free, D102N
2.5 Å, E217K
2.5 Å, E217K

0.40
0.37
1.30
1.27
1.25
1.21

class II slow forms and average Cα RMSDs for each residue of all the fast forms
of thrombin will give us a per residue Signal:Noise for all Cα RMSDs compared to the
1PPB control. This analysis shows that the class II structures show significant change in
conformation which can be attributed to the slow form of thrombin. The class I structures
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are conformationally indistinguishable from the Na+ bound fast form. A close analysis of
residues undergoing major conformational change reveals a positive correlation between
residues with high conformational change and their implication of being involved in
slow→fast allostery from kinetic and mutagenesis data. To no surprise, these residues
are in the Na+ binding site, active-site and exosite-I, strongly reinforcing the hypothesis
of allosteric communication between the three sites.98
It is very difficult to identify which among the class II structures is cognate to the
actual in-solution slow form, but inferences can be drawn from the structural
commonalities among these structures. All these structures show the Na+ binding loop
shifts more towards the active site cleft. This blocks the S1 pocket in all the structures.
Another feature is the reorganization of the aryl-binding pocket. In 1GP9 Trp215 is in a
conformation which would block P2 and P4 interactions, whereas in 1RD3, Trp215
protrudes slightly into the S4 pocket. Finally, all the class II structures exhibit the
destruction of the oxy-anion hole. The flipping of Gly193 leading to flipping of Glu192
results in a non-catalytic hydrogen bond with Ser195. All these observations explain the
biochemical data of substrates and inhibitors, especially the effect on S1 and aryl binding
site widening upon Na+ binding. The class II structures thus represent the slow form of
thrombin.
A corollary to the comparison between the slow and fast structures is the
observation that the residues involved in the conformational change are not disordered
but are stabilized by extensive but different hydrogen bonding interactions. It can be
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inferred from this that the two forms represent energetic minima in solution. The
observation of presence of catalytic activity even in absence of Na+ leads to the
hypothesis that there is a rapid and dynamic equilibrium between the catalytically
inactive and active forms of thrombin and the role of Na+ binding is to stabilize the active
form. The evidence for this came from experiments by Shafer et. al.71 which studies
change of intrinsic fluorescence upon Na+ binding. It was observed that the binding
profile was biphasic, with the fast phase within the dead time of the stop flow device and
the slow phase of ~30 s-1 which is independent of Na+ concentrations. The rate constant
of the slow phase was found to be dependent on temperature. At higher temperature the
binding profile is still biphasic but the ratio of fast:slow phase is similar to that obtained
at 5 ⁰C. The data fits the model of thrombin in two forms: one capable of Na+ binding

and the other incapable of Na+ binding, the transitioning from the later to the former

accounting for the temperature dependent slow phase. Gianni et. al. resolved a linear
dependence of the fast phase on Na+ concentration, implying that the conformational
change reported by Shafer et. al. precedes Na+ binding.99 The mechanism can be
described by the following equation:
E* ↔ E ↔ E:Na+
Where E* is the thrombin conformer incapable of Na+ binding and E is the conformer
capable of Na+ binding. This rationalizes the observed differences (and similarities) in
fast, slow(class I) and slow(class II) structures to be attributed to each of these forms can
be assigned to E:Na+, E and E* allosteric states, respectively. Gianni et. al. show that the
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ratio of E*:E is 1:1 in absence of Na+ and Na+ is simply acting to stabilize the E state.99
These recent findings have also led to a re-thinking of the “slow-fast” nomenclature
because E state, although it has no Na+ coordinated, is still catalytically active.
1.7 Sulfated Dehydropolymers: Novel Allosteric Inhibitors of Thrombin Acting via
Exosite-II
In the last five decades, heparins and Vitamin K epoxide reductase inhibitors have
been the mainstay for anticoagulant therapy. These anticoagulants suffer several
limitations. This anticoagulants inhibit thrombin activity by enhancing its inactivation by
ATIII (see section 1.5.1) or inhibiting thrombin biosynthesis. Vitamin K epoxide
reductase inhibitors like warfarin suffer from several limitations like drug-drug
interactions, drug-food interactions and high dose-response variability. Heparins on the
other hand are ineffective in inactivating clot-bound thrombin. Further, unfractionated
heparin (UFH) dose-response is highly variable due to its binding to plasma proteins.
Because of the key role of thrombin in procoagulant pathways, direct thrombin inhibitors
have recently received a lot of attention. Currently, only three DTI are approved by FDA
viz. hirudin and its synthetic congener bivalirudin, and argatroban. In an effort to design
new synthetic anticoagulants exploiting the template mechanism of heparin-induced
thrombin inhibition, our laboratory discovered dehydro-polymers which display very
interesting anticoagulant profile.
Dehydro-polymers are heterogeneous and polydisperse polymers of cinnamic
acids which were synthesized by a two step chemo-enzymatic means in a two step
protocol. In the first step coupling of cinnamic acid monomers is done using enzyme
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horseradish peroxidase (HRP). Three cinnamic acid derivatives were chosen for
homopolymerization viz. caffeic acid, ferulic acid and sinapic acid. Upon action of HRP,
various radical intermediates form, that further undergoes chain extension. Key among
these linkages are β-O-4 and β-O-5 linkage (although, β-β, 5-5 and 5-O-4 linkages are
also a possibility). In the second step, the polymers are sulfated using trialkyl aminesulfur trioxide complex. The resulting product is a heterogeneous and polydisperse
mixture of sulfated dehydro-polymers of caffeic acid (CDs), ferulic acid (FDs) and
sinapic acid (SDs) depending on the starting material used. (see Figure 16)
Prothrombin time (PT) and activated partial thromboplastin time (aPTT)
measurement in presence of each of the DHPs indicated that they are potent
anticoagulants. The DHPs were found to be 1.4 to 3.4 times more effective in prolonging
PT, but 2.2 to 3.8 times less effective in prolonging aPTT, as compared to LMWH, with
an overall higher effectiveness to prolong PT than aPTT. This implies that DHPs act on
the intrinsic pathway more than on extrinsic pathway.
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Among the DHPs, the anticoagulant potency follows the order: CDs>FDs>SDs. It is
possible that there is a positive correlation between the degree of structural diversity and
anticoagulant potency, CDs being the most diverse and SDs being least diverse.100, 101
Interestingly, direct and indirect enzyme inhibition studies revealed that the major
mechanism of coagulation is a selective inhibition of thrombin and fXa. This was a
surprise as these compounds were designed to mimic the template mechanism of ATIII
mediated thrombin inhibition similar to heparins. FDs, CDs and SDs showed nM IC 50
values for both thrombin and fXa in absence of ATIII. (see Figure 17 and Table 3)
Competitive inhibition studies for thrombin with heparins and C-terminal hirudin based
peptide showed that CDs showed higher competition with heparins as compared to hirudin
based peptide. This means that CDs have a preferentially bind to the exosite-II. Steady
state kinetic studies with different concentrations of CDs showed that the V max (and k cat )
decreased and the K m increased slightly when the CDs concentration was increased. It was
hypothesized based on this that CDs cause an allosteric disruption of catalytic triad.102

37

Figure 16. Chemoenzymatic synthesis of DHPs. CA, FA and SA stands for Caffeic acid,
Ferulic acid and Synnapic acid respectively. This figure was taken from Reference 100.
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Figure 17. Direct inhibition of fXa and Thrombin by CDs (solid triagles), FDs (square)
and CDs (solid dots). This figure was taken from Reference 102.
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Table 3. IC 50 values of inhibition of Thrombin, fXa, fIXa and fVIIa by various DHPs in
presence (direct) and absence (Indirect) of Antithrombin-III. This table was taken from
Reference 102.

The structural basis for this mechanism remains to be found in order to gain a better
understanding of this novel mechanism. One of the problems in doing this is the
heterogeneity inherent in the DHPs. To resolve this problem the lab recently synthesized
small molecules that represent the scaffold of one of the possible monomeric unit which
could comprise the putative DHPs structure. The compounds showed inhibition of
thrombin and fXa, with 4AS (see Figure 18) being the most active.

H3CO

O
CH3

NaO3SO
COONa
Figure 18. Structure of 4AS.
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1.8 Specific Aims of the Research
A) To Understand the Structural Basis of DHP Inhibition Using X-ray
Crystallography: Since 4AS represents one of the monomeric unit of DHPs, it is a good
starting point for initiating structure-based drug design. Our aim is to solve the structure of
4AS complexed with thrombin. The minimum information that could be derived from the
study is the location of binding site of 4AS on thrombin. Careful comparison of crystal
structure of native enzyme and its isomorphous soaks may reveal the structural changes
induced by the binding.
B) To Characterize Thrombin-Sucrose octasulfate Interaction by Biophysical and
Biochemical Methods: Thrombin-heparin interaction has been extensively studied by
fluorescence spectroscopy using active site fluorescent probe p-amino benzamidine. We
propose to use the same method to characterize thrombin-SOS interaction. SOS and
heparin have a sulfated sugar scaffold. Unlike heparin, sucrose octasulfate has higher
charge density. The effect of sugar chain length has been characterized using different
chain length heparins. We would like to determine the effect of charge density by studying
this interaction.

41

CHAPTER 2 CRYSTALLOGRAPHIC ANALYSIS OF 4AS-SOAKED
NATIVE BOVINE THROMBIN CRYSTALS AND HUMAN PPACK
THROMBIN- 4AS CO-CRYSTALS

2.1 Introduction
2.1.1 Overview of Drug-Protein Crystallography
Protein crystallography is a biophysical method used to generate accurate models
of proteins at atomic or near-atomic resolution. The wavelength of x-rays falls in the range
(~1.5 Å) appropriate to deduce information about inter-atomic distances from diffraction
scattering through interaction of the x-rays with the electrons of atoms. The method
involves passing of an x-ray beam through a high quality protein crystal of appropriate
size, and recording the diffraction pattern on an image plate or detector. By accurately
measuring the position and intensity of each spot on the diffraction pattern, it is possible
(with supplemental phase information) to construct a 3D map of electron density of the
repeat unit of the crystal (the unit cell). Once the electron density map is generated, it is
possible to build an accurate model of the molecule into this density.
The requirement of good quality protein crystals arises for two reasons: firstly,
single molecules give weak diffraction, and secondly, in solution molecules are in constant
motion which leads to a cancelling out diffracted x-rays. The repeated and periodic
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arrangement of atoms in a crystal enhances the signal of each diffracted x-ray so that it is
possible to measure its intensity with high statistical confidence levels.
Drug-protein crystallography adds an additional step in protein crystallography, in
that, at some point during the experiment the drug needs to be incorporated, which can be
done by adding appropriate concentrations of the drug in the crystallization buffer. This
method is called co-crystallization. Alternatively, a preformed native protein crystal can be
soaked in a solution that contains the drug. Unlike small molecule crystals, protein crystals
contain between 40 to 70 % solvent. If given enough time, the drug can diffuse through the
solvent channels and get incorporated into the crystal.103, 104
Drug-protein crystallography aids immensely to the process of structure-based drug
discovery. It gives atomic level information about interactions made by the drug with the
protein. Additionally, by comparing the structural differences in the drug-bound and
unbound crystal forms it is possible to understand the structural basis of drug action. The
information derived from the experiment can be further used to make modifications in the
lead structure. It is also possible to use the information in virtual screening and docking
studies of homologous series of compounds.105
2.1.2 Rationale for Specific Aim A
Since DHPs interact with thrombin at or near exosite-II it can be hypothesized that
4AS also would interact with that region. Since 4AS contains a sulfate and a carboxylate, it
is likely that a sizable contribution to the binding energy would be ionic in nature. To
avoid ionic screening effects, which could interfere in binding, it is necessary to screen for
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crystallizing conditions having low ionic strength. In order to identify the allosteric
changes induced by 4AS binding to thrombin, a native thrombin crystal has to be
crystallized for comparison. Solving the structure of 4AS soaks of native thrombin crystal
and comparing it with the native structure would unambiguously delineate the changes
induced by 4AS binding. If the structural changes are small and the difference between the
solution-form free energies of bound and unbound states are low, it is possible that the
changes could be masked due to stabilizing crystal contacts in a pre-formed crystal. It is
therefore also desirable to find a co-crystallizing condition for 4AS-thrombin complex.
It was surprising to find that among the ~550 thrombin structures deposited in the
PDB not a single structure was that of unliganded wild-type thrombin (in fast form). Most
of the information on thrombin structure has been derived from PPACK-thrombin and
hirugen-thrombin structures. Recently, Iyaguchi. et. al. reported preliminary crystallization
data of unliganded wild-type bovine thrombin.106 But, the group has not reported the
solved structure. It was proposed that these conditions be used for obtaining crystals for
subsequent soaking. Both the native and derivative structure would be solved and
compared. At the same time, small scale crystal trials to find co-crystallization conditions
of thrombin-4AS complex were also proposed.
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2.2 Results
2.2.1 Crystallization of Native Bovine thrombin and Human PPACK thrombin under
co-crystallization conditions with 4-AS
The crystals of native bovine thrombin obtained under the reported conditions were
of suboptimum size and unsuitable for diffraction experiments. (see Figure 19) This
necessitated further screening and optimization of these conditions. As seen in the Figure
19, under the reported conditions, there was significant protein precipitation and also a
high degree of nucleation. This leads to depletion of protein from the mother liquor by
protein precipitates and simultaneously growing crystal nuclei, and as a result, the crystals
fail to grow to larger dimensions. The goal of optimization was to achieve optimum size by
decreasing the nucleation and precipitation. This was done by a carefully changing each
condition variable, adding various additives and changing the experimental set-up (sittingdrop, micro-dialysis etc.) The crystals obtained after optimization are shown in Figure 20.
The results of the optimization trials are summarized in Table 4.
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Table 4. Result summary of optimization trials for native bovine thrombin crystals.
Condition Variable
PEG

2-Propanol
pH
Buffer concentration
Buffer substitution

Protein concentration
Drop Size
Crystallization method
Sitting drop
Sandwich drop
Micro-dialysis
Other adjuvants
Calcium 1mM, 5 mM
Glycerol 3, 5,10 % v/v

Observation
PEG 3350 gave large crystals without any
associated precipitates. Optimum
concentration was 20 % w/v. Crystal
formation under these conditions was
so rapid that crystals could be seen
immediately after the cover-slip was
placed over the reservoir!
Change in concentration did not affect the
amount of nucleation considerably
Optimum pH was 6.2 ± 0.2, pH lower than
5.8 lead to precipitation
Low concentrations of sodium citrate gave
precipitates
MES, PIPES, Cacodylate and Bis-tris were
used at pH 6.2 instead of sodium
citrate. No crystals formed in any
except in PIPES
Optimum concentration was between 4.5 to
6.5 mg/ml
Larger drops gave larger crystals
Large amount of nucleation
Same as hanging drop
Large amount of nucleation
Does not considerably affect the crystal
size
Increasing concentrations of glycerol gave
decreasing amounts of nucleation
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~0.075mm
Figure 19. Crystals of native bovine thrombin under previously reported conditions.106

~0.075mm
Figure 20. Crystals of native bovine thrombin obtained under optimized conditions.
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Figure 21. Human PPACK thrombin grown from crystallization buffer containing 4-AS.
Each graduation is approximately equal to 0.05 mm.

Bovine thrombin crystals were grown under conditions where there was possibility of
autolytic degradation. Since the crystals grew fairly quickly, autolytic degradation was not
anticipated. This was confirmed with SDS-polyacrylamide gel electrophoresis under
reducing conditions of the crystals which showed no signs of degradation. (see Figure 22)
. In order to screen co-crystallization conditions for thrombin-4AS complex, human
thrombin was covalently inhibited with PPACK. One such condition gave very large
crystals. (Human ppack thrombin form-I) Although these crystals showed signs of
epitaxial twinning at certain portions (see Figure 21), it was possible to perform the
diffraction experiment by using parts of the crystal which seemed to have grown from a
single nucleus.
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Figure 22. SDS polyacrylamide gel of native bovine thrombin crystals of different age and
the corresponding mother liquor solution in which they were grown.
2.2.2 X-ray Diffraction Experiments
Complete data-sets of native bovine thrombin, bovine thrombin-4AS soaks and
human ppack thrombin crystal form-I were collected for several crystals, out of which the
best data was chosen for further analysis. Analysis of the systematic absences showed that
the native bovine thrombin crystals and its 4AS derivatives belong to space-group P4 3 2 1 2
or P4 1 2 1 2 with unit cell parameters a = b = 87.64 Å, c = 194.51 Å; α = β = γ = 90⁰; and a =
b = 87.64 Å, c = 195.99 Å;α = β = γ = 90 ⁰ respectively. The R merge of the native and the
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derivative was calculated to be 16.7 % and 15.3 % respectively. Human ppack thrombin
crystal form-I belonged to orthorhombic space-group P2 1 2 1 2 1 having unit cell dimensions
of a = 44.36 Å, b = 73.78 Å, c = 100.29α Å;
= β = γ = 90

⁰. The R merge was 17 %.

Preliminary diffraction data for the three crystals is summarized in the Table 5.
Table 5. Preliminary diffraction data of native bovine thrombin, bovine thrombin-4AS
soak and human ppack thrombin form-I.
Parameter
Native bovine
Bovine thrombinHuman-PPACK
thrombin
5AS soak
thrombin form-I
Space group
P4 2 2 or P4 1 2 1 2
P4 2 2 or P4 1 2 1 2
P2 2 2
3 1

Unit cell parameters

3 1

1 1 1

a=b=87.64 ,
c=194.51
α=β=γ=90⁰
39.20-2.8 (2.9-2.8)

a=b= 87.64,
c=195.99
α=β=γ=90⁰
40-2.5 (2.59-2.5)

Number of observed
reflections
Unique reflections
Completeness(%)
R
(%)

69882

133569

a= 44.36, b= 73.78,
c =100.29
α=β=γ=90⁰
38.02 –2.7 (2.80 2.70)
40521

16696
85.9 (97.7)
16.7 (30.8)

27046
99.1 (99.9)
15.3 (35.2)

8843
92.5 (98.6)
17 (41.6)

Cell Volume (cubic
Å)

1494137.3

1505275.75

328260.594

Resolution (Å)

merge

2.2.3 Structure determination
Models obtained from molecular replacement solution of native bovine thrombin,
bovine thrombin-4AS soak and human PPACK thrombin crystal form-I, were refined to an
R factor below 0.3. The refined model statistics for each structure, are given in Table 6.
The Ramachandran plot for each of the structures is shown in Figures 23-25 . R factors
and Ramachandran plot indicate that the models are consistent with the experimental data
and allowed bonding geometries respectively. Moreover, examination of 2F o -F c map
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shows that most of the density is accounted for by the model. A detailed examination of
the electron density map revealed no density for ligand in both bovine thrombin-4AS soaks
as well as human PPACK thrombin crystal form-I.

Table 6. Refined model statistics for native bovine thrombin, bovine thrombin-4AS soak,
and human PPACK thrombin crystal form-I structures.
Native bovine
Bovine thrombin
Human PPACK
thrombin
soaks
thrombin
R factor
0.23
0.24
0.27
R free
0.29
0.30
0.37
% reflections in test 10
10
5
set
Bond length rmsd
0.007
0.012
0.009
(Å)
Bond angles rmsd
1.027
1.48
1.26
(deg)
Dihedral angles
18.367
19.27
21.16
rmsd (deg.)
Planarity rmsd
0.004
0.006
0.006
Chirality rmsd
0.075
0.092
0.084
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Figure 23. Ramachandran plot of refined native bovine thrombin structure. Plot was
generated using RAMPAGE.115
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Figure 24. Ramachandran plot of refined bovine thrombin-4AS soak structure. Plot was
generated using RAMPAGE.115
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Figure 25. Ramachandran plot of refined human PPACK thrombin form-I. The plot was
generated using RAMPAGE.115
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2.3 Experimental
2.3.1 Crystallization of Native Bovine thrombin and Human PPACK thrombin-4AS
co-crystals
Bovine thrombin and human thrombin were purchased from Haematologic
Technologies Inc. (Essex Junction, VT). They were supplied in vials containing 10mg/ml
thrombin in 50 % v/v glycerol solution. PPACK was purchased from BioMol Inc. Bovine
thrombin was exchanged with 10 mM Tris-HCl, pH 8.0, and 50 mM NaCl using Amicon
YM-10 ultracentrifugation tubes. The protein solution was stored in 10 μl aliquots at -80⁰C
for future use. Human thrombin was diluted to 1 mg/ml using 0.2 M Phosphate buffer, pH
6.5, and incubated with a 10-fold molar excess of PPACK for 20 min at 20 ⁰C. The
solution was then exchanged with 2 mM MOPS buffer, pH 7, 0.1 M NaCl and 0.05 % w/v
NaN 3 . The solution was concentrated to 10 mg/ml concentration and stored at 4 ⁰C.
Initial crystals of native bovine thrombin were obtained using the conditions
reported by Iyaguchi et. al. by hanging drop vapor diffusion using 3 μl reservoir and 3 μl
protein solution. The reservoir solution consisted 500 μl of 0.1 M sodium citrate, pH 5.6,
15 % w/v PEG 4000 and 20 % w/v 2-propanol. Tetragonal-bipyramidal crystals of
dimensions 0.05 mm x 0.05 mm x 0.05 mm were obtained in two days at 25 ⁰C.
Optimization of this condition was done by changing various parameters as listed
in Table 7. Apart from the conditions listed in the table, crystallization was also tried with
different crystallization methods like sitting-drop, sandwich drop and micro-dialysis and
different pH conditions (5.5 to 7.0). Optimized crystals of 0.125 x 0.125 x 0.125 mm size
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Table 7. Different conditions used to optimize the crystallization of native bovine
thrombin crystals. pH under all conditions was 6.2.
Condition [Sodium Citrate]
[2-Propanol]
[PEG 3350]
Other additive
#
(M)
(v/v)
(w/v)
1.
0.1
5
20
2.
0.1
10
20
3.
0.1
15
20
4.
0.1
20
20
5.
0.1
25
20
6.
0.1
15
19.5
7.
0.1
15
20.5
8.
0.1
15
20
5 mM CaCl 2
9.
0.1
15
20
1 mM CaCl 2
10.
0.1
15
20
3 % v/v Glycerol
11.
0.1
15
20
5 % v/v Glycerol
12.
0.1
15
20
10 % v/v Glycerol
13.
0.05
15
20
14.
0.1
15
20
3 % v/v MPD
15.
0.1
15
20
5 % v/v MPD
16.
0.1
20
10 % v/v MPD
17.
0.1
20
15 % v/v MPD
18.
15
20
0.1 M MES
19.
15
20
0.1 M Cacodylate
20.
15
20
0.1 M PIPES
were obtained by hanging-drop vapor diffusion using 3 μl reservoir and 3 μl protein
solution in one and a half day at 25 ⁰C. The reservoir solution consisted of 500 μl of 0.1 M
sodium citrate, pH 6.2, 20 % w/v PEG 3350 and 15 % v/v 2-propanol.
Human PPACK thrombin crystal form-I, was obtained using hanging-drop vapor
diffusion method. 3 μl of solution containing 5 mg/ml human PPACK thrombin incubated
overnight with a 10 fold molar excess of 4AS was mixed with 3 μl of reservoir solution.
Reservoir consisted of 500 μl of 0.1 M Tris-HCl, pH 8.5 and 25 % v/v t-butanol. Large
crystals of 0.25 mm x 0.25 mm x 1.5 mm were obtained in a week at 20 ⁰C.
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2.3.2 Data Collection
Diffraction experiments were performed on Raxis IV (Rigaku Americas Co.) under
cryo-cooling conditions at 100 K. Native bovine thrombin crystals grown as described in
the previous section, were swiftly taken out from the mother liquor using a nylon loop and
flash-frozen under a stream of liquid nitrogen on the goniometer head. The crystals did not
require cryo-protection due to the presence of 2-propanol in the mother liquor, which acts
as a cryo-protecting agent. Indexing of initial still frames indicated a tetragonal space
group, which requires a minimum data of 45⁰. Since redundant data was desirable, the
diffractometer was programmed to collect 0.5⁰ oscillation frames from φ angles 0⁰ to 180⁰
at 0.5⁰ intervals (360 frames) and an exposure time of 15 minutes and crystal-to-detector
distance of 150 mm. Once the data collection was complete, the data was integrated using
d*trek program under the CrystalClear software package (Rigaku Americas Co.).
Complete data-sets were collected on several single crystals and the best data set was used
for structure determination.
In order to prepare 4AS derivatives of native crystals, three hanging drops
containing increasing concentrations of 4AS (with the highest concentration of 5mM 4AS)
in the mother liquor were equilibrated against a reservoir solution for a day. The next day,
native bovine thrombin crystals which were previously grown were consecutively
transferred into the pre-equilibrated drops containing increasing concentrations of 4AS.
The crystals were soaked in each drop for 2 hours. After the third soaking step, the crystals
were mounted on the goniometer head as described for native bovine thrombin crystals.
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0.5⁰ oscillation frames were collected from φ angles 0 to 180⁰ at intervals of 0.5⁰ and
exposure time of 10 minutes and crystal-to-detector distance of 150 mm. The data was
integrated, scaled and merged using d*trek. Two data sets were collected using single
crystals, the best of which was used for structure determination.
Initial diffraction experiments on Human PPACK thrombin crystal form-I showed
that the crystals required cryo-protection. Cryo-protection was achieved by fast,
consecutive transfers of the crystal in increasing concentrations of glycerol (10 % v/v, 15
% v/v, 20 % v/v) in mother liquor, using a nylon loop, after which the crystal was
immediately mounted on goniometer head. 0.5⁰ oscillation frames from 0⁰ to 180⁰ were
collected using exposure time of 5 minutes and crystal to detector distance of 110 mm. The
data was integrated, scaled and merged using d*trek. Several data sets were collected.
Some of the crystals showed overlapping diffraction patterns indicating cracking of crystal
or presence of epitaxial twinning. The best data-set was used for determining the structure.
The data collection protocols for native bovine crystals, its 4AS derivatives and human
PPACK thrombin crystal form-I are summarized in Table 8.
Merged reflections from d*trek are in the form of intensities. The intensities were
converted to amplitudes using TRUNCATE program in CCP4 program suite 6.1.0.107 In
doing so, the program assumes negative intensities as zero and takes a square-root of the
reflection intensities. Analysis of Matthew’s coefficient probabilities108 suggested two
molecules of bovine thrombin per asymmetric unit and one molecule of human PPACK
thrombin per asymmetric unit.
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Table 8. Data collection protocol
Parameter

Native bovine
thrombin

Bovine thrombin4AS soaks

150 mm

5 mM β-5MSC in
mother liquor
150 mm

Human PPACK
thrombin formI
To 20 %
glycerol in steps
Crystal grown in
1 mM β-5MSC
110 mm

Cryo-protecting
conditions
Soaking conditions

Not required

Not required

Crystal to detector
distance
Exposure time
Start and end angle

15 min
0⁰ – 180⁰

10 min
0⁰ – 180⁰

5 min
0⁰ - 180⁰

-

2.3.3 Structure determination
An automated molecular replacement (MR) search was done using PHASER 2.1 in
the molecular replacement module of CCP4. The coordinates of L and H chains of 1MKX
were used as a search model for native bovine thrombin and 4AS soak. Single solutions
were obtained for space group P4 3 2 1 2 for native bovine thrombin and its 4AS derivative.
High log likelihood gains (LLG) and translation function Z-scores (TFZ) indicated that the
solution found were correct.
Previously solved structure of human PPACK thrombin (PDB ID: 1PPB) was used
as a search model for MR for human PPACK thrombin from-I. Single solution was found
in P2 1 2 1 2 1 space group. The summary of phasing by molecular replacement is shown in
Table 9.
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Table 9. Molecular replacement summary.

Search model
(PDB ID)
Sequence identity
Nmol/assymetric
unit
RF Z
TFZ
LLG

Native bovine
thrombin
1MKX

Bovine thrombin5AS soaks
1MKX

Human PPACK
thrombin form-I
1PPB

100%
2

100 %
2

100 %
1

11.3
50.3
2035

14.6
19.5
2034

19.9
33.7
1245

In order to remove phase bias from the models obtained from molecular
replacement, initial cycle of refinement was done using simulated annealing in Phenix 1.43109. For human PPACK thrombin structure, simulated annealing in CNS 1.2 was used
rather than phenix. This was because the human PPACK thrombin data is of relatively low
resolution. At low resolution there is a higher parameter:observables ratio which can lead
to over-refinement. Phenix.refine uses a cartesian coordinate refinement. This has higher
number of refinement parameters, increasing the possibility of over-fitting at low
resolution, as the number of observables is low relative to the parameters being refined.
The models obtained from simulated annealing were examined in Coot 0.5.2
against weighted 2F o -F c (at 1σ contour level) and F o -F c (at 3σ contour level) difference
maps.110 The model was manually fit to 2F o -F c density using utilities in Coot. This was
followed by a restrained refinement in REFMAC 5.5. This cycle of manual fitting followed
by restrained refinement was repeated until no further improvement in the model was
observed. To guide this process the R and R free were monitored throughout the process.
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2.4 Discussion
Reasons for the absence of density to account for 4AS were investigated. One
possible reason could be that the affinity of ligand is diminished in the crystallization
buffer. But, since the two structures that were solved, were from crystal forms grown in
significantly different buffer, pH and ionic strengths; the chances of this being the case is
low and could point to a general low affinity of 4AS towards thrombin. The affinity of
4AS could not be determined using the fluorescent probe para amino-benzamidine due to a
high amount of interference from 4AS. From the fluorescence experiments, it was also
observed that 4AS did not give any change in fluorescence emission in presence or absence
of thrombin. This precluded the determination of 4AS affinity using reverse titrations.
Another possibility could be that the crystallographic contacts might be blocking the
binding site of 4AS. Examining the packing arrangement of the asymmetric unit and its
neighboring symmetry related molecules, in both the structures, revealed a fully free and
solvent exposed exosite-II. (see Figure 26) It is possible; however, that 4AS binds to a site
other than exosite-II which might be unavailable for binding.
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Figure 26. Asymmetric unit of bovine thrombin-4AS soak structure (green) shown along
with neighboring symmetry related molecules (grey). The white circle shows unhindered,
solvent-exposed exosite-II region.

If the occupancy of the 4AS is low, complete density may not show up. This could
especially become problematic in the case where model has large difference between R
and R free , as in the case of the PPACK thrombin form-I. The quality of this model was
determined by examining 2F o -F c omit maps contoured at 1σ. Omit maps showed good
density for all parts of the model (see Figure 27), except for the 149-loop which was
disordered.
It was recently found (after the determination of both the crystal structures) that
4AS inhibited the hydrolysis of chromogenic substrate by thrombin very weakly (~20%
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inhibition of thrombin hydrolysis of chromogenic substrate spectrozyme-TH) at milli
molar concentrations.111 This suggests a weak binding affinity of the ligand towards
thrombin and can explain its absence in the electron density map solved by
crystallography.

Figure 27. 2F o -F c omit map contoured at 1σ overlaid on FPR fragment in human PPACK
thrombin crystal form-I.

In the process of finding the structure of 4AS bound to thrombin, the crystal
structure of unliganded native bovine thrombin was determined. The unliganded thrombin
structure had not been previously reported due to the autolytic degradation of thrombin in
the crystallization drop when stored for a long time. This did not happen under these
conditions, possibly due to a rapid crystallization rate. Crystals attain maximum size within
3 days.
63

Although the structure was solved at a low resolution, several important aspects of
the structure could be determined. The structure showed strong density for sodium at the
sodium binding site indicating that both monomers in the asymmetric unit were sodium
bound. Cα superposition of residues of the refined model on L and H chains of 1MKX
shows an identical topology. (see Figure 28) Superposition of the active site catalytic triad
is shown in Figure 29.

Figure 28. Overlay of protein backbone of bovine thrombin from 1MKX and solved
structure
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Figure 29. The catalytic triad of L and H chain of 1MKX (blue) superposed on the solved
native bovine thrombin structure (green).
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CHAPTER 3 BIOPHYSICAL AND BIOCHEMICAL CHARACTERIZATION OF
THROMBIN-SUCROSE OCTASULFATE INTERACTION

3.1 Rationale for Specific Aim B
Thrombin-heparin interaction has been previously characterized by monitoring the
change in fluorescence intensity of the active site fluorescent probe para-amino
benzamidine (PABA). Sucrose octasulfate (SOS) has a sulfated sugar scaffold and would
be expected to interact with thrombin in a manner similar to heparin. We propose to find
the equilibrium dissociation constant of SOS using the fluorescent probe PABA. By
determining the dissociation constant of SOS at different salt concentrations, it is possible
to determine the ionic contribution to binding energy. By comparing the salt dependence of
SOS-thrombin and heparin-thrombin interaction, which was previously reported,112 the
effect of high charge density of SOS on interaction with exosite-II can be understood.
Since SOS has no physiologically relevant anticoagulant property, the binding of
SOS to exosite-II can be exploited to compete with inhibitors binding to exosite-II, and
therefore can be envisioned as an antidote for such inhibitors. To explore this potential,
competitive enzyme-inhibition experiments with DHPs were designed. Also, combined
with the competitive enzyme inhibition experiments, indirect inference of the approximate
site of DHP binding can be deduced by solving a crystal structure of thrombin complexed
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with SOS. Conditions used to determine native bovine thrombin structure (see section 2.3)
can be used to obtain co-crystals of SOS complexed with thrombin.
3.2 Determination of Equilibrium Dissociation Constant (K D ) and Salt Dependence
for Thrombin-Sucrose Octasulfate Interaction
3.2.1 Results
Fluorescence equilibrium binding titration of SOS with thrombin-PABA complex
showed a concentration dependent and saturable change (quenching) of thrombin-PABA
fluorescence which could be fitted to a quadratic binding isotherm as shown in the
equation below:

where, ΔF/F o is the fractional change in fluorescence emission as compared to initial
fluorescence F o where no ligand is present; [P] o is the protein concentration used; [L] o is
the concentration of the ligand, SOS in this case; K Dobs is the observed equilibrium
dissociation constant and ΔF max is the maximal change in fluorescence emission.
The binding isotherms for three different salt concentrations were fitted on the
experimental data using Sigma-plot and are shown in Figures 30-32. The K D value
determined for each experiment is given in the Table 10.
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Figure 30. Binding isotherm of sucrose octasulfate for thrombin at 50 mM NaCl.

Figure 31. Binding isotherm of sucrose octasulfate for thrombin at 150 mM NaCl
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Figure 32. Binding isotherm of sucrose octasulfate for thrombin at 250 mM NaCl.
Table 10. K Dobs values of sucrose octasulfate-thrombin interaction at different salt
concentrations.
[NaCl] (M)
K Dobs (μM)
ΔF max
0.05
0.15
0.25

1.4 ± 0.3
22.1 ± 4.1
148.1 ± 24.7

-0.048 ± 0.001
-0.064 ± 0.003
-0.092 ± 0.006

3.2.2 Experimental
Human thrombin was purchased from Haematologic Technologies (Essex Junction,
VT) and used as such. Para-amino benzamidine and sodium sucrose octasulfate was
purchased from Sigma-Aldrich and BIOMOL international (Plymouth Meeting, PA).
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Fluorescence binding titrations were performed in 20 mM Phosphate buffer, 0.1 mM
EDTA and 0.1 % PEG 8000 and three different concentrations of NaCl (0.05 M, 0.15 M,
and 0.25 M). Acrylic cuvettes coated with PEG 20,000 were used for this purpose. The
QM-4 configuration in spectrofluorimeter (PTI ltd.) was used and the experiments were
carried out at a constant temperature of 25 ⁰C. The excitation and emission wavelengths of
345 nm and 370 nm respectively and excitation and emission band-pass of 4 nm and 8 nm
respectively were selected for the experiments. Each reading was corrected for dilution and
background fluorescence of PABA.
3.3 Competitive Enzyme Inhibition Assays of DHPs in Presence of Sucrose
Octasulfate
3.3.1 Results
IC 50 values of FDs in presence of increasing concentrations of SOS were
determined using chromogenic substrate Spectrozyme-TH. Semi-logarithmic plots were
fitted to the equation given below:

where, Y is the fractional residual proteinase activity in presence of inhibitor to its absence.
Y M and Y o are the maximum and minimum possible values of the fractional residual
proteinase activity, IC 50 is the concentration of inhibitor that leads to a 50 % inhibition of
enzyme activity and HS is the Hill slope.
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The fitted plots showed characteristic sigmoidal shape seen in a standard doseresponse curve. It was observed that the graph was shifted to the right as the concentration
of SOS used in the experiment increased a characteristic behavior of competitive binding.
(see Figure 33) However the extent to which the plot is shifted slowly diminishes as the
concentration of SOS increases. The IC 50 values are listed in Table 11.

Figure 33. Inhibition of thrombin by FDs in absence and presence of SOS. Each data point
is represented by different shaped symbols as shown in the legend. The fit is shown by
different colored smooth lines.
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Table 11. IC 50 values of FDs for thrombin in the presence of various concentrations of
SOS.
[SOS] (μM)

IC

50

Yo

YM

HS

0

0.8

35.1

102.2

0.9

50

1.8

47.2

98.7

0.9

100

1.9

56.5

101.7

1.0

200

2.7

45.2

99.9

0.9

While measuring the residual thrombin activity of control which contained SOS but
no DHPs, it was found that SOS itself inhibited thrombin, with the highest inhibition of
~12% seen at 200 μM. To investigate this behavior further, enzyme inhibition assay similar
to that used for FDs was performed. The experiment showed that SOS inhibited thrombin
with an IC 50 of 3.8 μM with maximal inhibition of 12.8 %. A semi-logarithmic plot fitted
according to the equation given above is shown in Figure 34.
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Figure 34. Inhibition of thrombin activity by SOS. Data points used to generate fit
(smooth line) are shown by solid circles.

3.3.2 Experimental
Spectrozyme-TH was purchased from American Diagnostica (Greenwich, CT).
FDs was synthesized in our lab by the protocol of Monien et. al.100 Competitive assays of
inhibition of thrombin proteinase activity by FDs were done in presence of three different
concentrations of SOS (50 μM, 100 μM and 200 μM). An assay where no SOS was present
served as control. 15 stock solutions at concentrations from 0.12 μM to 4 mM FDs
(concentration calculated using an average molecular weight of 4120 Da) were prepared.
10 μl of each solution was added to 930 μl of phosphate buffer, pH 7.4, 0.1 mM EDTA,
0.1 % v/v PEG 8000 and 0.15 M NaCl in PEG 20,000 coated cuvettes to which 1 μl of
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SOS stocks (which make appropriate final SOS concentration) was added. 10 μl of human
thrombin (500 nM) was added to each cuvette and mixed. After 10 minutes of incubation,
30 μl of 1 mM Spectrozyme-TH was added successively to each cuvette, rapidly mixed
and the residual enzyme activity was determined by measuring the initial rate of increase in
absorbance at 405 nM. Residual proteinase activity relative to negative control where no
FDs or SOS was present was calculated for each concentration of FDs. IC 50 values for
control, 50 μM SOS, 100 μM SOS and 200 μM SOS were measured by fitting the data
from each of the respective experiment to the equation shown in section 3.4.1

Enzyme inhibition assays for determining IC 50 of SOS were performed using the
same procedure used to determine the IC 50 of DHPs. Stock solutions containing different
concentration of SOS ranging from 97 μM to 20 mM were used instead of FDs.
3.4 Crystal Structure Determination of Thrombin-Sucrose octasulfate Complex
3.4.1 Results
The preliminary data for SOS-bovine thrombin co-crystal is shown in the Table 12.
After successful molecular replacement the structure was refined to an R and R free value of
0.23 and 0.28 respectively. The Ramachandran plot of the refined model is shown in
Figure 35.
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Table 12. Preliminary diffraction data of bovine thrombin-SOS co-crystals
Parameter
Space group

Native bovine thrombin
P4 3 2 1 2

Unit cell parameters

a=b=87.56 , c=191.99
α=β=γ=90⁰
27.92-2.2(2.28-2.2)
304797

Resolution (Å)
Number of observed
reflections
Unique reflections
Completeness(%)
R merge (%)

38745
99.8 (100)
8.3 (31.1)

Cell Volume (cubic
Å)

1472000.543
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Figure 35. Ramachandran plot of the refined structure of bovine thrombin-SOS cocrystals. The plot was generated using RAMPAGE.115
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Examining the 2F o -F c and F o -F c maps revealed clear density for Na+ and various
ordered water molecules in and around the Na+ binding site. The two Na+ ions were put
into the model. At the same time, waters showing clear density in the 2F o -F c map along
with positive density in F o -F c and making at least one contact with the protein were also
incorporated into the model. It was observed that there were two large blobs of density
close to exosite-II showing up in both the 2F o -F c and F o -F c maps. SOS was built into both
these regions of densities. The sulfate groups on SOS were fit first followed by the sugar
ring. After refinement, the 2F o -F c map showed a good fit for both the SOS molecules. It
should be noted that the density for SOS was weak and it was not possible to ascertain
features like ring puckering and binding conformation for the two SOS molecules. In order
to make sure that SOS was correctly fit, 2F o -F c omit maps, contoured at 1σ were
generated. The omit maps showed only broken density for the two sucrose octasulfate
molecules, with missing density on the sugar backbone. Interestingly, the density seen in
the omit maps was in the region of SOS that interacts with the protein, indicating these
regions to be more ordered.
The two molecules of SOS (SRC1 and SRC2) interact with exosite-II of the two
thrombin monomers (A and B) forming the asymmetric unit. SRC1 interacts with both the
monomers, while SRC2 makes exclusive interactions with exosite-II of one of the
monomers (A). (see Figure 37) Careful examination of electron density around the two
SOS molecules shows that SCR2 makes an ionic hydrogen bond with His91(A) and
electrostatic interaction with Lys236(A). Density for these interactions is also present in
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the 2F o -F c omit maps. The residues within interacting distance of the two SOS molecules
are Arg93(A), Lys101(A), Lys126(B), Lys235(B), Arg240(A) Lys240 (A) and Arg244(A).
(see Figure 38)

Figure 36. Interaction of two SOS molecules(SCR1 and SCR2) with two thrombin
monomers (A and B) in the asymmetric unit. 2F o -F c map contoured at 1σ is shown for
SCR1 and SCR2.
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Figure 37. Thrombin residues in interaction distance of the two SOS molecules: SRC1 and
SRC2 (shown in stick representation overlaid with 2Fo-Fc map contoured at 1 σ). The
letter in parenthesis indicates the thrombin monomer to which each residue belongs.

Examination of the difference maps showed that the occupancy of the SOS
molecules was below 1. This could be due to weak or non-specific binding. Since it was
possible that citrate ions, present in the buffer, which has a moderately high charge-density
might be interfering with binding. An additional data-set was collected in which the citrate
was exchanged with cationic buffer bis-tris. Preliminary data for this crystal is given in
Table 13. The model obtained from this data also showed two large electron density blobs
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at the same location as that found in the previous structure. This strongly increases the
confidence in the SOS molecules fit in the previous structure.
Table 13. Preliminary diffraction data for bovine thrombin-SOS co-crystals exchanged in
bis-tris.
Parameter
Space group
P4 3 2 1 2
Unit cell parameters
Resolution (Å)
Number of observed
reflections
Unique reflections
Completeness(%)
R merge (%)

a=b=87.76 , c=190.62
α=β=γ=90⁰
39.86 – 2.3 (2.38 – 2.3)
408377
33783
99.5 (100)
15.5 (37.7)

3.4.2 Experimental
Bovine thrombin obtained from Haematologic Technologies (Essex Junction, VT)
and processed as described in section 2.3.1 was diluted to a concentration of 7 mg/ml using
0.01 M Tris-HCl, pH 8.0, 0.05 M NaCl. It was incubated for an hour with 20 mM SOS and
this solution containing 20mM SOS and 7 mg/ml thrombin was used for crystallization
under the optimized condition described to crystallize native bovine thrombin. (see section
3.2.1) Crystals of 0.5 mm x 0.5 mm x 0.5 mm dimensions grew at 25 ⁰C, from hanging
drops, containing 4 μl of thrombin-SOS mixture and 4ul of reservoir. Reservoir was
composed of ingredients listed in condition # 3 of Table in section 3.2.1.
Frames from φ angles of 0 to 180⁰, at 0.5⁰ intervals, were collected from a single
crystal which diffracted beyond 2.2 Å resolution. The data were integrated, scaled and
merged using d*trek. Preliminary analysis of the data showed a space group of P4 3 2 1 2 as
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was the case with native bovine thrombin crystals. One of the unit cell dimensions (c) was
considerably different as compared to native crystals and 4AS soaks.
The reflection intensities were converted to amplitudes using TRUNCATE107 and
the resulting file was used to perform molecular replacement using coordinates of 1MKX
as search model, as described previously for native bovine thrombin crystals and 4AS
derivatives. The search gave a single solution in P4 3 2 1 2 space group and two molecules
per asymmetric unit. The model generated from molecular replacement was initially
refined by simulated annealing in phenix.refine. The structure was further refined by cycles
of manual refinement in Coot 0.5.2110 using weighted difference maps and restrained
refinement in REFMAC 5.2.
Another dataset was collected on SOS-bovine thrombin co-crystal grown under
condition # 9 (Table 7), but before data collection, the citrate buffer was replaced by 0.05
M bis-tris (keeping all the other conditions including SOS concentration same) by gradual,
step-wise exchange. The crystals diffracted to 2.4 Å resolution. The structure was solved
and refined to an R factor and R free of 0.24 and 0.30 respectively as described above.
3.5 Discussion
SOS at salt concentration of 150 mM, which is close to the physiological
concentration of NaCl, has a K D of ~ 22 μM. Comparing this with similar chain length
heparin fragment shows that SOS interacts with far greater affinity than heparin. The
closest heparin homolog in terms of chain length is a tetrasaccharide. Its K D is reported to
be 71±6 μM.112 On an average there is 2 times higher charge density on SOS compared to
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heparin which could be the reason for lower K D . It has been previously reported that the
presence of negatively charged groups on the ligands enhances the binding of ligand with
exosite-I and exosite-II. This is due to the presence of a net dipole on these sites. It is
possible that higher charge density on SOS leads to a faster associate rates (k on ). Although
this may not have strong implications in designing better heparinoid mimetics, it adds one
more piece of information to the understanding of the nonspecific interaction mechanism
of ligands with thrombin exosite-II.
The interaction of polyanionic ligand with protein can be illustrated by the following
equation:

where P is the protein concentration, L is the polyanionic ligand concentration, Z the
number of charged interactions made by the ligand with the protein, Ψ is the fraction of
monovalent counterion bound per activator ionic charge that is released on protein binding
and can be taken as 0.8. M+ is the monovalent cation released when L binds to P. The K D
for such equilibrium can be described by the following equation:
=
Rearranging this gives:
logK D(obs) = logK D(Non-ionic) + ZΨlog[Na+]
Plotting logK D(obs) vs Ψlog[Na+] gives a straight line with slope of Z and yintercept of logK D(Non-ionic). The above equation was used to determine the value of K D(Nonionic)

and Z (number of ionic interactions per number of ligand bound) for SOS interaction
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with thrombin. Figure 38 shows the plot of logK Dobs vs Ψlog[NaCl] for 50 mM, 150 mM
and 250 mM NaCl. Fitting a straight line through the data-points gave a slope of 3.54 and a
Y-intercept of -2.045. (see Figure 38) This means that the thrombin-SOS interaction has

log[KDobs]

approximately 3.54 charged interactions and a K D(Non-ionic) of 6.2 mM.

Ψlog[Na+]
Figure 38. Salt dependence plot of thrombin-SOS interaction.
Competitive experiments with FDs described in section 3.4 can be quantitatively analyzed
by the Dixon-Webb relationship given by the following equation:

A true competitor would shift the log dose-response curve to the right by a magnitude
depending on the K D and concentration of the competitor as described by this relationship.
Using the K D determined in section 3.1 and the experimental IC 50 values measured at
different concentrations of SOS we can calculate IC 50calc . Table 14 shows IC 50calc values.
A graphical representation of the representation of this is shown in Figure 39. Clearly SOS
83

is not a true competitor of FDs. The heterogeneous nature of FDs and the fact that SOS
itself inhibits thrombin, further complicates this analysis.
Table 14. Comparision of IC 50measured and IC 50calc .
[SOS] μM
IC 50 measured (μM)
0
0.8
50
1.8
100
1.9
200
2.7

IC 50 calc (μM)
0.8
4.2
10.5
26.7

Figure 39. Graph of IC 50measured measured experimentally at different concentrations of
SOS(blue) and IC 50calc calculated using Dixon-Webb relationship.
Determination of the structure of bovine thrombin complexed with sucrose
octasulfate shows two SOS molecules bound to thrombin. The additional structure solved
without citrate, which was thought to interfere in the binding also revealed density for SOS
at the same site as that solved in the previous structure. It should be noted that the density
observed in the absence of citrate was not more well-defined than that observed with
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citrate suggesting that the binding is still weak and possibly has multiple binding
orientations.
Comparing the neighboring residues to the fitted SOS molecules, shows that SCR2
interacts only with thrombin monomer A and SCR1 interacts with exosite-II of both
thrombin monomers (A and B). However, the interacting surface of SCR1 with monomer
B is small compared to monomer A. It is possible that the interaction with thrombin
monomer B is an artifact of crystal packing. SCR2 interacts with monomer A in a similar
mode to the interaction of heparin octasaccharide with exosite-II. (see Figure 40)
In order to correlate the inhibition of thrombin cleavage of chromogenic substrate
(section 3.4) with the structure results, the Cα residues of the refined structure was
superposed on 1MKX. No significant difference was found except for the 149-loop. The
149-loop has been reported to be disordered in various structures previously published. In
the current structure it was also found to be disordered. For most of its residues, density
was only observed for the protein back-bone. No differences were found when the active
site residues (His57, Asp102, and Ser195) were superposed on the corresponding residues
of 1MKX.
It is possible that the conformational change may have been masked due to crystal
packing in this crystal form. Many previously reported structures of thrombin bound to
exosite ligands fail to show any conformational change, even when in-solution studies
indicate an allosteric perturbation of structure.47, 76, 113 In a recently reported structure of
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thrombin complexed with suramin which was shown to inhibit thrombin by binding to
exosite-II, the thrombin molecule did not show any significant conformational change.85

Figure 40. Interaction of sucrose octasulfate molecule SCR2 (stick representation) with
thrombin monomer (semi-transparent electrostatic surface representation). Important
thrombin residues are also shown in stick representation and are labeled.

3.6 Conclusion and Significance of Work
Refined structures of bovine thrombin-4AS soaks and human PPACK thrombin4AS co-crystals were solved. The structure did not show any density for the ligand. In the
process a new crystal form of native bovine thrombin in unliganded state was solved. This
crystal form can be used to study thrombin-ligand interactions, especially for ligands
binding to exosite-II, since it is not involved in any crystallographic contacts.
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K D of SOS for thrombin was determined using fluorescence spectroscopy with the
secondary probe PABA. The K D was significantly lower than heparin fragment of
comparable size. The salt dependence of K D revealed that a significant contribution to the
binding energy is due to ionic forces. The number of charge interaction per molecule of
SOS bound to thrombin was calculated to be 3.5. Competitive enzyme inhibition
experiments of FDs using increasing concentrations of FDs were carried out. It was found
that there was ~2-3 fold increase in the IC 50 of FDs at the highest concentration of SOS
used (200 μM). Based on the Dixon-Webb relationship it was found that SOS is not an
ideal competitor for FDs.
The crystal structure of bovine thrombin cocrystallized with SOS showed two
molecules of SOS bound to the two thrombin molecules in the asymmetric unit via exositeII. One of the SOS molecules which was bound exclusively to one thrombin monomer
showed interactions very similar to that made by heparin octasachharide. Key among the
interactions are Lys236, His91, Arg93 and Arg101. Characterization of this interaction
novel interaction mode of sucrose octasulfate adds to our current evidence of compounds
binding to exosite-II like heparin, but unlike heparin showing direct inhibitory properties.
3.7 Future Direction
Recent studies have shown that 4AS is a more effective inhibitor for fXa than for
thrombin. Crystallographic analysis of 4AS bound to fXa could be pursued. The optimized
conditions for obtaining bovine thrombin crystals can be exploited for future soaking or
co-crystallization experiments with tighter binding compounds based on the DHPs
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scaffold. Apart from crystallography, in order to gain a better understanding of the
allosteric mechanism of DHPs, a chromogenic substrate library can be used to identify
changes in substrate specificity induced by the DHPs. Such work has been extensively
reported by Vindigni et. al.114 Since SOS was found to inhibit thrombin, steady state
kinetic studies study could shed light on its mode of thrombin inhibition.
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